Toxicity of busulfan and cyclophosphamide (BU/CY2) in patients with hematologic malignancies

Bone Marrow Transplant. 1996 Mar;17(3):329-33.

Abstract

Between July 1991 and January 1994, 52 patients with hematologic malignancies underwent BMT using BU/CY2 as conditioning regimen. Median patient age was 38 years. Eleven patients underwent autologous BMT, 22 HLA-identical allogeneic BMT, and 19 patients underwent a MUD or an allogeneic mismatched BMT. GVHD prophylaxis was with cyclosporine/methylprednisone in 26 patients; T cell depletion was used in 15 patients. VOD was observed in 7.5% of patients, IP in 12%, seizures in 4%. The overall incidence of grade II-IV acute GVHD was 35%. Delayed platelet engraftment was observed in seven of 11 patients who underwent autologous BMT. Graft failure was seen in seven of 19 (37%) patients who underwent MUD or allogeneic mismatched BMT. Six of the seven patients received T cell depletion as GVHD prophylaxis. BU/CY2 transplantation from an unrelated or family-mismatched donor with T cell depletion is associated with a high incidence of graft failure.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents, Alkylating / adverse effects*
  • Bone Marrow Transplantation*
  • Busulfan / adverse effects*
  • Combined Modality Therapy
  • Cyclophosphamide / adverse effects*
  • Drug Therapy, Combination
  • Female
  • Graft vs Host Disease / epidemiology
  • Humans
  • Leukemia / drug therapy*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / drug therapy*
  • Pneumonia / etiology
  • Risk Factors
  • Vascular Diseases / chemically induced

Substances

  • Antineoplastic Agents, Alkylating
  • Cyclophosphamide
  • Busulfan